{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:53:10Z","timestamp":1762005190897,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ymgme.2020.06.002","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T21:36:39Z","timestamp":1591392999000},"page":"227-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Fabry disease during the COVID-19 pandemic. Why and how treatment should be continued"],"prefix":"10.1016","volume":"130","author":[{"given":"Juan","family":"Politei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2020.06.002_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis."},{"issue":"11","key":"10.1016\/j.ymgme.2020.06.002_bb0010","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"issue":"11","key":"10.1016\/j.ymgme.2020.06.002_bb0015","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"issue":"11","key":"10.1016\/j.ymgme.2020.06.002_bb0020","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2020.06.002_bb0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40259-015-0116-7","article-title":"Enzymes approved for human therapy: indications, mechanisms and adverse effects","volume":"29","author":"Baldo","year":"2015","journal-title":"BioDrugs."},{"issue":"7","key":"10.1016\/j.ymgme.2020.06.002_bb0030","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1517\/14712598.4.7.1167","article-title":"Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase a orphan products and one FDA approval","volume":"4","author":"Desnick","year":"2004","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"5","key":"10.1016\/j.ymgme.2020.06.002_bb0035","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","article-title":"Migalastat: a review in Fabry disease","volume":"79","author":"McCafferty","year":"2019","journal-title":"Drugs."},{"key":"10.1016\/j.ymgme.2020.06.002_bb0040","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/BF01825509","article-title":"Zur klinik und Aitiologie des Angiokeratoma","volume":"123","author":"Fabry","year":"1916","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.ymgme.2020.06.002_bb0045","unstructured":"Fabry J. Weiterer Beitrag zur Klinik des Angiokeratoma Naeviforme (Naevus angiokeratosusj). Derm Wochenschr1930; 90: 339\u2013341."},{"issue":"3","key":"10.1016\/j.ymgme.2020.06.002_bb0050","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1164\/ajrccm.155.3.9116979","article-title":"Pulmonary involvement in Fabry disease","volume":"155","author":"Brown","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.ymgme.2020.06.002_bb0055","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/0002-9343(80)90224-7","article-title":"Chronic airflow obstruction in Fabry\u2019s disease","volume":"68","author":"Rosenberg","year":"1980","journal-title":"Am. J. Med."},{"issue":"5","key":"10.1016\/j.ymgme.2020.06.002_bb0060","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s10545-007-0616-9","article-title":"Natural history of the respiratory involvement in Anderson-Fabry disease","volume":"30","author":"Magage","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2020.06.002_bb0065","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2143\/AC.65.2.2047052","article-title":"Cardiopulmonary involvement in Fabry\u2019s disease","volume":"65","author":"Koskenvuo","year":"2010","journal-title":"Acta Cardiol."},{"key":"10.1016\/j.ymgme.2020.06.002_bb0070","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/thorax.55.8.720","article-title":"Induced sputum examination: diagnosis of pulmonary involvement in Fabry\u2019s disease","volume":"55","author":"Kelly","year":"2000","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.ymgme.2020.06.002_bb0075","first-page":"681","article-title":"Fabry\u2019s disease. A correlative clinical, morphologic, and biochemical study","volume":"18","author":"Bagdade","year":"1968","journal-title":"Lab. Investig."},{"key":"10.1016\/j.ymgme.2020.06.002_bb0080","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2559.1991.tb01510.x","article-title":"Pulmonary vasculature in Fabry\u2019s disease","volume":"19","author":"Smith","year":"1991","journal-title":"Histopathology."},{"issue":"6","key":"10.1016\/j.ymgme.2020.06.002_bb0085","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/crj.12446","article-title":"Long time enzyme replacement therapy stabilizes obstructive lung disease and alters peripheral immune cell subsets in Fabry patients","volume":"11","author":"Odler","year":"2017","journal-title":"Clin. Respir. J."},{"issue":"8","key":"10.1016\/j.ymgme.2020.06.002_bb0090","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ejim.2013.05.003","article-title":"Pulmonary involvement in Fabry disease: overview and perspectives","volume":"24","author":"Franzen","year":"2013","journal-title":"Eur. J. Intern. Med."},{"issue":"7","key":"10.1016\/j.ymgme.2020.06.002_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180437","article-title":"Long-term follow-up of pulmonary function in Fabry disease: a bi-center observational study","volume":"12","author":"Franzen","year":"2017","journal-title":"PLoS One"},{"issue":"Suppl. 2","key":"10.1016\/j.ymgme.2020.06.002_bb0100","doi-asserted-by":"crossref","first-page":"S369","DOI":"10.1007\/s10545-008-0930-x","article-title":"Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage","volume":"31","author":"Wang","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2020.06.002_bb0105","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ajmg.a.31600","article-title":"Pulmonary manifestations of Fabry disease and positive response to enzyme replacement therapy","volume":"143","author":"Kim","year":"2007","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgme.2020.06.002_bb0110","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s10545-006-0361-5","article-title":"Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease","volume":"29","author":"Bierer","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2020.06.002_bb0115","article-title":"Pulmonary involvement in Fabry disease: effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy","volume":"5","author":"Franzen","year":"2018","journal-title":"BMJ Open Respir. Res."},{"key":"10.1016\/j.ymgme.2020.06.002_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2020.04.002","article-title":"Impact of COVID-19 related healthcare crisis on treatments for patients with lysosomal storage disorders, the first Italian experience","author":"Sechi","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2020.06.002_bb0130","article-title":"Interruption of enzyme replacement therapy in Fabry disease: unfavorable outcome","volume":"3","author":"Cabrera","year":"2011","journal-title":"Neurol. Arg."},{"issue":"2","key":"10.1016\/j.ymgme.2020.06.002_bb0135","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jpeds.2007.02.057","article-title":"Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease","volume":"151","author":"Drelichman","year":"2007","journal-title":"J. Pediatr."},{"issue":"16","key":"10.1016\/j.ymgme.2020.06.002_bb0140","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1002\/ajmg.a.31831","article-title":"Rapid deterioration of a patient with mucopolysaccharidosis type I during interruption of enzyme replacement therapy","volume":"143A","author":"Wegrzyn","year":"2007","journal-title":"Am. J. Med. Genet. A"},{"issue":"3","key":"10.1016\/j.ymgme.2020.06.002_bb0145","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ymgme.2012.08.013","article-title":"Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature","volume":"107","author":"Jurecka","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.ymgme.2020.06.002_bb0150","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ymgme.2013.08.019","article-title":"Effect of rapid cessation of enzyme replacement therapy: a report of 5 more cases","volume":"111","author":"Jurecka","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2020.06.002_bb0155","article-title":"Enzyme replacement therapy interruption in patients with Mucopolysaccharidoses: recommendations for distinct scenarios in Latin America","volume":"23","author":"Solano","year":"2020","journal-title":"Mol Genet Metab Rep."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719220301414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719220301414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:25:12Z","timestamp":1761089112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719220301414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S1096719220301414"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2020.06.002","relation":{},"ISSN":["1096-7192"],"issn-type":[{"type":"print","value":"1096-7192"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fabry disease during the COVID-19 pandemic. Why and how treatment should be continued","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2020.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}